Statistically Motivated Second Order Pooling

Second-order pooling, a.k.a.~bilinear pooling, has proven effective for deep learning based visual recognition. However, the resulting second-order networks yield a final representation that is orders of magnitude larger than that of standard, first-order ones, making them memory-intensive and cumbersome to deploy. Here, we introduce a general, parametric compression strategy that can produce more compact representations than existing compression techniques, yet outperform both compressed and uncompressed second-order models. Our approach is motivated by a statistical analysis of the network's activations, relying on operations that lead to a Gaussian-distributed final representation, as inherently used by first-order deep networks. As evidenced by our experiments, this lets us outperform the state-of-the-art first-order and second-order models on several benchmark recognition datasets.Comment: Accepted to ECCV 2018. Camera ready version. 14 page, 5 figures, 3 table

On the generalized vector F-implicit complementarity problems and vector F-implicit variational inequality problems

In this paper, we introduce and analyze some new classes of generalized vector-F implicit complementarity problems and the general mixed vector-F variational inequalities. Under suitable conditions, we prove the equivalences between these new problems. We establish several existence theorems for these classes of vector-F complementarity and general mixed vector-F variational inequalities using a new version of the Fan-KKM theorem in Hausdorff topological vector spaces, and without even using the classical assumptions in this context, like monotonicity or continuity. Results obtained in this paper represent significant improvement and refinement of the previously known results

New kinds of generalized variational-like inequality problems in topological vector spaces

AbstractIn this work, we consider a generalized nonlinear variational-like inequality problem, in topological vector spaces, and, by using the KKM technique, we prove an existence theorem. Our result extends a theorem of Ahmad and Irfan [R. Ahmad, S.S. Irfan, On the generalized nonlinear variational-like inequality problems, Appl. Math. Lett. 19 (2006) 294–297]

Clinical Efficacy and Toxicity of Anti-EGFR Therapy in Common Cancers

Epidermal growth factor receptor (EGFR) is a cell surface molecule and member of the ErbB family of receptor tyrosine kinases. Its activation leads to proliferation, antiapoptosis, and metastatic spread, making inhibition of this pathway a compelling target. In recent years, an increasing number of clinical trials in the management of solid malignancies have become available indicating the clinical efficacy of anti-EGFR monoclonal antibodies and oral small molecule tyrosine kinase inhibitors (TKIs). This review addresses frequently used EGFR inhibitors, summarizes clinical efficacy data of these new therapeutic agents, and discusses their associated toxicity and management

The relative frequency, clinical and laboratory findings of adult glomerulonephritidies in Tehran

Background: Renal diseases information is population-based and has great geographic variability. Due to the lack of national renal data registry system, there is no information on the prevalence rate, and clinical and laboratory features of various glomerulonephritidies (GNs) in Iran. Methods: In a retrospective cross sectional study, we analyzed 462 adult renal biopsies in Hashemi Nejad hospital, Tehran, Iran. We determined the prevalence rate and the frequency of different clinical and laboratory findings in patients with different GNs. We also compared our results with the reports from other countries. Results: There were 267(57.8) males and 195(42.2) females. The mean age (± SD) was 33.6 ± 15.7 (range, 13-75) years old. After exclusion of 55 biopsies with pathologies other than GNs and in the remaining 407 biopsies, membranous glomerulopathy (MGN) was the most common GN (23.6), followed by IgAN (13.5), membranoproliferative GN (11.5), systemic lupus nephritis (10.6), focal segmental glomerulosclerosis (10.3), and minimal change disease (9.8). These 6 GNs comprised the majority (79.4) of all GNs. Conclusion: MGN is the most common form of GN, followed by IgAN, MPGN, SLE-GN, FSGS and MCD in adult patients in our study. The multi-center studies with a larger sample size are needed for more comprehensive data in Iranian population

A Generalization of a Greguš Fixed Point Theorem in Metric Spaces

We first introduce a new class of contractive mappings in the setting of metric spaces and then we present certain Greguš type fixed point theorems for such mappings. As an application, we derive certain Greguš type common fixed theorems. Our results extend Greguš fixed point theorem in metric spaces and generalize and unify some related results in the literature. An example is also given to support our main result

A dose-dependent plasma signature of the safety and immunogenicity of the rVSV-Ebola vaccine in Europe and Africa.

The 2014-2015 Ebola epidemic affected several African countries, claiming more than 11,000 lives and leaving thousands with ongoing sequelae. Safe and effective vaccines could prevent or limit future outbreaks. The recombinant vesicular stomatitis virus-vectored Zaire Ebola (rVSV-ZEBOV) vaccine has shown marked immunogenicity and efficacy in humans but is reactogenic at higher doses. To understand its effects, we examined plasma samples from 115 healthy volunteers from Geneva who received low-dose (LD) or high-dose (HD) vaccine or placebo. Fifteen plasma chemokines/cytokines were assessed at baseline and on days 1, 2 to 3, and 7 after injection. Significant increases in monocyte-mediated MCP-1/CCL2, MIP-1β/CCL4, IL-6, TNF-α, IL-1Ra, and IL-10 occurred on day 1. A signature explaining 68% of cytokine/chemokine vaccine-response variability was identified. Its score was higher in HD versus LD vaccinees and was associated positively with vaccine viremia and negatively with cytopenia. It was higher in vaccinees with injection-site pain, fever, myalgia, chills, and headache; higher scores reflected increasing severity. In contrast, HD vaccinees who subsequently developed arthritis had lower day 1 scores than other HD vaccinees. Vaccine dose did not influence the signature despite its influence on specific outcomes. The Geneva-derived signature associated strongly (ρ = 0.97) with that of a cohort of 75 vaccinees from a parallel trial in Lambaréné, Gabon. Its score in Geneva HD vaccinees with subsequent arthritis was significantly lower than that in Lambaréné HD vaccinees, none of whom experienced arthritis. This signature, which reveals monocytes' critical role in rVSV-ZEBOV immunogenicity and safety across doses and continents, should prove useful in assessments of other vaccines